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Abstract 
Furosemide is a diuretic drug widely used in chronic renal failure. The drug has low solubility and 
permeability, which cause clinical problems. Studying the in vitro release performance elucidates the rate 
and extent of drug dissolved from dosage forms under different conditions. Furosemide reference tablets 
were tested using USP Apparatuses 1 and 2 as well as the flow-through cell method (USP Apparatus 4), a 
dissolution apparatus that simulates the human gastrointestinal tract better than the other methods. 
Dissolution profiles were created with USP Apparatuses 1 and 2 at 25, 50, and 75 rpm and 900 mL of 0.1 M 
hydrochloric acid, acetate buffer (pH 4.5), and phosphate buffer (pH 6.8). USP Apparatus 4 with a laminar 
flow of 16 mL/min and 22.6 mm cells was used. Drug dissolution was quantified at 274 nm for 60 min. 
Mean dissolution time, dissolution efficiency, time to 50 % dissolution, and time to 80 % dissolution data 
were used to compare dissolution profiles. Additionally, zero-order, first-order, Higuchi, Hixson-Crowell, 
Makoid-Banakar, and Weibull models were used to adjust furosemide dissolution data. Between USP 
Apparatus 1 and 2, significant differences were observed in almost all parameters at 50 and 75 rpm (p < 
0.05). A similar dissolution profile (f2 > 50) with a pharmacopoeial dissolution method (USP Apparatus 2 at 
50 rpm and 900 mL of phosphate buffer pH 5.8) and USP Apparatus 4 (laminar flow of 16 mL/min, 22.6 mm 
cells, and pH 6.8) was observed. The Weibull function was the best mathematical model to describe the in 
vitro release performance of furosemide in the three USP dissolution apparatuses. These results could be 
used to manufacture better furosemide dosage forms and decrease the negative clinical impact of current 
furosemide formulations. 
©2020 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/4.0/). 
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Introduction 
Furosemide is a diuretic drug widely used in the treatment of oedematous states associated with 
cardiac, chronic renal failure, hypertension, congestive heart failure, and cirrhosis [1]. Furosemide is a weak 
acid (pKa = 3.8) with low solubility and permeability [2]. According to the Biopharmaceutical Classification 
System, drugs with these characteristics belong to class IV [3]. The chemical structure of furosemide is 
shown in Figure 1. 
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Factors that affect drug bioavailability related to 
the pharmaceutical dosage form and manu-
facturing process have been described [4-5]. 
Techniques and strategies for the development of 
class IV drug formulations have also been discussed 
[6]. This information can support the design of 
better oral dosage forms of furosemide than those 
currently available. The oral bioavailability of 
furosemide has been reported to be 37–51 % [7] 
and 60–70 %, with a variable and erratic absorption [8]. For the reference product Lasix®, an absolute 
bioavailability of 56 % has been observed [9]. This limited bioavailability could be associated with significant 
differences in the dissolution behaviour of furosemide commercial formulations shown by several authors. 
Kaojarern et al. [10] reported an in vitro dissolution study of 13 brands of furosemide tablets (40 mg), of 
which only four fulfil the Q pharmacopoeial specification. Stüber et al. [11] studied the bioavailability of 
four furosemide drug products, of which three formulations have bioavailabilities of 81–83 % and lower in 
vitro dissolution performance than the reference in each of following conditions: pH 7.8/paddle at 25 rpm, 
pH 7.8/paddle at 50 rpm, pH 5.3/paddle at 50 rpm, and flow-through cell (100 mL/h)/pH 7.8. The difference 
in in vitro dissolution is more pronounced at pH 5.3/paddle at 50 rpm. Currently, the official dissolution test 
for furosemide tablets is the USP Apparatus 2 at 50 rpm with 900 mL of phosphate buffer pH 5.8 and no 
less than 80 % should be dissolved at 60 min [12]. A biowaiver monograph has been reported to waiver the 
in vivo bioequivalence of furosemide solid oral dosage forms by in vitro dissolution studies; however, given 
the available data, Granero et al. [3] concluded that a biowaiver procedure for this drug cannot be justified. 
Low solubility and permeability are problematic characteristics of class IV drugs; thus, the determination 
of in vitro release performance using different agitation rates, dissolution media, and dissolution 
apparatuses provides important information for improving the manufacture and evaluation of generic 
formulations. Despite the wide use of USP basket and paddle apparatuses (USP Apparatus 1 and 2, 
respectively) to monitor the physical quality of tablets and capsules, several investigations about the 
hydrodynamic environment that surrounds oral formulations have reported that these USP apparatuses do 
not adequately reproduce the natural environment of the gastrointestinal tract [13-15]; thus, it is necessary 
to document the in vitro release performance of poorly soluble drugs under different conditions to 
establish, in the best possible way, the environment in which the solid dosage forms will be within the 
gastrointestinal tract. Further, alternative apparatuses must be developed to achieve this goal. The flow-
through cell method (USP Apparatus 4) has been introduced as a dissolution apparatus to elucidate the rate 
and extent of the dissolution of drugs with low solubility under sink conditions [16]. USP Apparatus 4 is 
more reliable, reproducible, and discriminative than the other methods [17], and it generates a 
hydrodynamic environment similar to that inside the gastrointestinal tract [18]. Furthermore, an in vitro/in 
vivo correlation (IVIVC) has been established between the in vitro data generated with this apparatus and in 
vivo parameters [19,20]. 
The aim of this study was to evaluate the in vitro release performance of furosemide reference tablets in 
the hydrodynamic environments generated by different USP apparatuses and dissolution media of 
physiological relevance to identify the rate and extent of furosemide dissolution under these conditions. 
This information will reflect the characteristics of the reference drug product that can be considered in the 
preparation of a generic formulation. Lasix® tablets were tested with 0.1 M hydrochloric acid, acetate 
buffer (pH 4.5), and phosphate buffer (pH 6.8) using USP Apparatuses 1 and 2 (at different agitation rates) 
and USP Apparatus 4. 
 
Figure 1. Chemical structure of furosemide. 
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Experimental 
Materials 
Lasix® furosemide tablets (Sanofi-aventis de Mexico, S.A. de C.V., Mexico City, Mexico) were used. 
Mexican health authorities have designated this formulation as a reference product to be used in 
dissolution and bioequivalence studies [21]. 
Reagents 
Hydrochloric acid, sodium acetate, acetic acid, and phosphate salts were purchased from J.T. Baker-
Mexico (Xalostoc, Mexico). Furosemide reference standard was purchased from Sigma-Aldrich Co. (St. 
Louis, MO, USA). All samples were filtered through 0.45 µm nitrocellulose filters (Millipore, Ireland). 
Standard solutions were prepared by serial dilutions of the stock solutions of furosemide (1 mg/mL) to 
achieve concentrations of 1.25–20 µg/mL. The dissolution media comprised 0.1 N hydrochloric acid, acetate 
buffer (pH 4.5), and phosphate buffer (pH 6.8). 
Content uniformity and assay 
Content uniformity and assay tests were performed with the drug product according to the procedures 
described in the USP [12]. 
USP basket and paddle apparatus 
Dissolution profiles of furosemide were obtained using USP Apparatuses 1 and 2 (Model AT-7 Smart, 
Sotax, Basel, Switzerland) with 25, 50, and 75 rpm agitation rates. Additionally, pharmacopoeial dissolution 
conditions (USP Apparatus 2 at 50 rpm with phosphate buffer (pH 5.8)) were tested [12]. An ultraviolet-
visible (UV/Vis) spectrophotometer (Model Lambda 35, Perkin Elmer, USA) with 1 mm flow cells was used. 
The equipment was controlled by specific software designed by Sotax. Furosemide tablets were sprinkled 
on 900 mL of 0.1 N hydrochloric acid, acetate buffer (pH 4.5), and phosphate buffer (pH 6.8) at 37.0 ± 0.5 
°C. Samples were taken automatically every 5 min for 60 min. Dissolved furosemide was quantified with 
standard calibration curves, in each dissolution medium, at 274 nm. 
Flow-through cell method 
Dissolution profiles of furosemide were obtained with USP Apparatus 4 (Model CE6, Sotax AG, Basel, 
Switzerland) with 22.6 mm cells (i.d.). The laminar flow (originated with 6 g of glass beads) of 16 mL/min 
was tested. The dissolution media also comprised 0.1 M hydrochloric acid, acetate buffer (pH 4.5), and 
phosphate buffer (pH 6.8) at 37.0 ± 0.5 °C. Samples were taken automatically every 5 min for 60 min. 
Dissolved furosemide was quantified in a UV/Vis spectrophotometer (Model Lambda 10, Perkin Elmer, USA) 
with 1 mm cells at 274 nm. For every trial, and depending on the schedule work, a standard calibration 
curve in 0.1 N hydrochloric acid, acetate buffer (pH 4.5) or phosphate buffer (pH 6.8) was prepared. 
Dissolution data analysis 
Dissolution profiles were compared with model-independent and model-dependent approaches. For 
model-independent comparisons, mean dissolution time (MDT) and dissolution efficiency (DE) were 
calculated. MDT is the time to dissolve 63.2 % of the drug and was calculated according to the statistical 
moment’s theory [22,23]. Other authors have indicated the MDT to be 62–64 % [24]. DE is the area under 
the dissolution curve up to a certain time, t, expressed as a percentage of the area of the rectangle 
described by 100 % dissolution in the same period [25]. Both parameters were calculated with the Excel 
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add-in DDSolver program [26]. 
For model-dependent comparisons, dissolution data were adjusted to a hyperbole equation (y = ax/b+x) 
and, using a and b parameters, time to 50 % dissolution (t50%) and time to 80 % dissolution (t80%) were 
calculated. The fit was calculated using SigmaPlot software (version 11.0). For a complete comparison of 
dissolution data by a model-dependent approach, dissolution data were fitted to zero-order, first-order, 
Higuchi, Hixson-Crowell, Makoid-Banakar, and Weibull models. The model with the highest adjusted 
determination coefficient (R2adjusted) and lowest Akaike information criterion (AIC) is the best-fit model [27]. 
Data analysis was carried out using Excel add-in DDSolver program [28]. All statistical comparisons were 
carried out with Student’s t-tests with significant differences at p < 0.05. 
Results 
Content uniformity and assay 
The drug product used met the content uniformity and assay tests specified in the USP. The percentage 
of furosemide in the content uniformity test ranged from 97.4–100.31 % (pharmacopoeial criteria, 85–115 
%) and that in the assay test was 100.79 % (criteria, 90–110 %) [12]. 
Dissolution profiles with USP basket and paddle apparatus 
Dissolution profiles of furosemide obtained with the USP Apparatuses 1 and 2 at different agitation rates 
and in different dissolution media are shown in Figure 2. 
A limited amount of furosemide dissolved in 0.1 M hydrochloric acid at 60 min with both USP dissolution 
apparatuses (< 20 %). Almost 60 % of the drug dissolved using USP Apparatus 2 at 75 rpm with acetate 
buffer (pH 4.5) as the dissolution medium. A complete release of the drug was achieved using phosphate 
buffer (pH 6.8) at 50 and 75 rpm, independent of the USP apparatus used. To compare dissolution profiles 
between USP Apparatuses 1 and 2, model-independent and -dependent parameters, at pH 6.8, were 
calculated, the results of which are shown in Table 1. 
At 25 rpm and with both USP apparatuses, less than 65 % of furosemide dissolved; thus, the t80% was not 
calculated. At this agitation rate, significant differences in MDT values were observed (p < 0.05). At 50 rpm, 
significant differences in all calculated parameters were observed (p < 0.05). These results suggest a 
complete non-equivalence in the dissolution performance of furosemide between USP Apparatuses 1 and 2 
at these conditions (pH 6.8 and 50 rpm). At 75 rpm, significant differences in MDT, DE, t50%, and t80% values 
were observed (p < 0.05). Higher values of MDT, t50%, and t80% were observed with USP Apparatus 1 than 
with USP Apparatus 2, at 50 and 75 rpm; these findings could be attributed to slower in vitro dissolution 
rates in USP Apparatus 1. Dissolution data at pH 6.8, adjusted with different mathematical models, are 
shown in Table 2. 
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Figure 2. Dissolution profiles of furo-
semide reference tablets using USP 
Apparatuses 1 and 2 with dissolution 
media in physiological pH range. Mean, 
n = 6. 
Table 1. Model-independent and -dependent parameters of furosemide at pH 6.8. Mean ± SEM, n = 6. 
Agitation rate (rpm) Parameter USP Apparatus 1 USP Apparatus 2 
25 
Diss. at 60 min (%) 64.61 ± 1.64 62.98 ± 5.87 
MDT (min) 18.94 ± 0.16 17.11 ± 0.42* 
DE (%) 44.42 ± 1.18 45.15 ± 4.49 
t50% (min) 31.09 ± 1.89 33.07 ± 8.47 
t80% (min) † † 
50 
Diss. at 60 min (%) 93.90 ± 2.23 101.76 ± 0.54* 
MDT (min) 15.00 ± 0.81 4.99 ± 0.14* 
DE (%) 70.56 ± 2.85 93.30 ± 0.43* 
t50% (min) 11.15 ± 1.35 2.07 ± 0.11* 
t80% (min) 32.27 ± 4.02 6.75 ± 0.30* 
75 
Diss. at 60 min (%) 102.43 ± 0.30 102.02 ± 0.48 
MDT (min) 7.49 ± 0.41 3.42 ± 0.01* 
DE (%) 89.64 ± 0.77 96.20 ± 0.45* 
t50% (min) 4.13 ± 0.30 0.72 ± 0.02* 
t80% (min) 11.95 ± 0.75 2.58 ± 0.08* 
*p < 0.05. †Data not calculated 
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25 0.5474 0.8935 0.9731 0.8155 0.9938 0.9997 
50 -0.2118 0.9725 0.8774 0.8929 0.9932 0.9996 
75 -3.99 0.9492 -0.2872 0.6144 0.9281 0.9994 
AIC 
25 87.76 69.95 53.49 76.81 37.07 1.85 
50 104.11 56.38 74.14 74.83 42.38 8.99 
75 117.66 60.73 101.10 85.25 66.30 0.64 




25 0.3232 0.7889 0.9521 0.6872 0.9952 0.9976 
50 -17.85 0.9611 0.8774 -1.85 0.9932 0.9999 
75 -144.29 0.7176 -50.97 -31.37 0.9016 0.9998 
AIC 
25 90.15 73.14 55.70 79.54 27.37 17.52 
50 120.96 36.84 74.14 98.05 42.38 -34.36 
75 123.27 42.04 110.92 105.23 37.35 -40.46 
Considering the established criteria to choose the best-fit model (higher R2adjusted and lower AIC values), 
the Weibull function was the best mathematical equation to describe all dissolution data at pH 6.8. The 
expression of this function is as follows [26]: 
𝐹 = 𝐹max [𝑒
−
(𝑡−𝑇𝑖)𝛽
𝛼 ] , (1) 
where F is the percent of the drug that dissolved vs. t time, Fmax is the maximum percent of the drug that 
dissolved at infinite time, α is the scale factor of the process, β is the shape factor, and Ti is a location 
parameter of time in which the drug begins to dissolve. The furosemide dissolution data of both USP 
apparatuses adjusted to the Weibull model dissolution profiles were statistically compared with Td values 
derived from fitting to this equation. The Td value represents the time interval necessary to dissolve or 
release 63.2 % of the drug present in the pharmaceutical dosage form [25] and coincides with MDT if the 
dissolution rate-time curve can be approximated by a monoexponential equation [22]. The mean values of 
α, β, Ti, Fmax, and Td are shown in Table 3. Significant differences were observed in all comparisons (p < 
0.05). 
Table 3. Weibull parameters and Td values at pH 6.8. Mean, n = 6. 
Agitation rate (rpm) α β Ti Fmax Td ± SEM (min) 
USP Apparatus 1 
25 10.25 0.63 3.12 95.48 50.15 ± 9.38 
50 5.81 0.59 2.70 111.03 22.78 ± 3.93 
75 13.30 1.15 0.72 102.43 7.64 ± 0.43 
USP Apparatus 2 
25 30.04 0.94 -0.11 70.50 25.63 ± 3.51* 
50 2.75 0.84 1.53 101.76 4.72 ± 0.18* 
75 1.87 0.77 -0.39 102.03 1.80 ± 0.12* 
*p < 0.05. 
Model-dependent comparisons (by comparing Td values) indicated that USP Apparatuses 1 and 2 at 50 
and 75 rpm generated different dissolution profiles. As both USP dissolution apparatuses and agitation 
rates created different hydrodynamic environments, these results were expected. 
Dissolution profiles with flow-through cell method 
Dissolution profiles of furosemide reference tablets using USP Apparatus 4 with 0.1 M hydrochloric acid, 
acetate buffer (pH 4.5), phosphate buffer (pH 6.8), and laminar flow of 16 mL/min are shown in Figure 3. 
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Figure 3. Dissolution profiles of furosemide 
reference tablets using USP Apparatus 4 
with dissolution media in physiological pH 
range. Mean ± SD, n = 12. 
With the flow-through cell method, less than 20 % of furosemide dissolved when 0.1 M hydrochloric 
acid and acetate buffer (pH 4.5) were used, whereas almost 90 % of the drug was released with phosphate 
buffer (pH 6.8). Slower dissolution rates with USP Apparatus 4 than with USP Apparatuses 1 and 2 have 
been found; however, in this case, a dissolution medium with low pH was an important factor for the low 
dissolution of furosemide. As more than 80 % of the drug dissolved at 60 min at pH 6.8 and, for 
comparative purposes, the dissolution profile of furosemide tablets was obtained using a pharmacopoeial 
method. A test was carried out with USP Apparatus 2 at 50 rpm with 900 mL of phosphate buffer (pH 5.8) 
(Q = 80 % at 60 min), the results of which are shown in Figure 4. 
 
Figure 4. Dissolution profiles of furosemide 
reference tablets using the pharmacopoeial 
conditions (USP 2) and flow-through cell 
method (USP 4) with different dissolution 
media. Mean ± SD, n = 12. 
Under official conditions, the furosemide tablets met the Q pharmacopoeial specification (> 80 % 
dissolved at 60 min). The dissolution profiles of USP Apparatuses 2 and 4 were similar (f2 > 50). This result 
suggested that a pharmacopoeial method (USP Apparatus 2) can produce a similar dissolution profile to 
that obtained with equipment (USP Apparatus 4) that generates a hydrodynamic environment similar to 
that inside the gastrointestinal tract and for which a correlation with in vivo data has been shown [19,20]. 
For a complete comparison between the profiles, model-independent and -dependent parameters were 
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calculated and statistically compared, the results of which are shown in Table 4. 
Table 4. Model-independent and -dependent parameters of furosemide. Mean ± SEM, n = 12. 
Parameter USP Apparatus 2 (pH 5.8) USP Apparatus 4 (pH 6.8) 
Diss. at 60 min (%) 102.55 ± 0.61 89.49 ± 1.50* 
MDT (min) 15.61 ± 0.68 15.28 ± 1.06 
DE (%) 75.93 ± 1.52 66.57 ± 1.44* 
t50% (min) 10.86 ± 0.79 13.35 ± 1.10 
t80% (min) 25.99 ± 1.50 36.64 ± 2.34* 
*p < 0.05. 
Significant differences were observed in percent dissolved at 60 min, DE, and t80% values (p < 0.05), 
whereas there was no difference in MDT and t50%, between USP Apparatuses 2 and 4. If we consider MDT 
and t50% as parameters that reflect the in vitro dissolution rate, this is similar between the conditions (USP 
Apparatus 2 at 50 rpm and phosphate buffer (pH 5.8)/USP Apparatus 4 with a laminar flow of 16 mL/min 
and phosphate buffer (pH 6.8)), at least until the time at which 63.2 % of the drug is dissolved. Furosemide 
dissolution data obtained with pharmacopoeial conditions and the flow-through cell method, adjusted to 
mathematical models, are shown in Table 5. 













2 (pH 5.8) 0.1571 0.9788 0.9152 0.9882 0.9770 0.9994 
4 (pH 6.8) 0.0115 0.9205 0.8048 0.8488 0.9743 0.9991 
AIC 
2 (pH 5.8) 104.08 58.28 75.30 52.62 30.04 8.29 
4 (pH 6.8) 101.87 66.11 81.14 74.67 57.47 15.79 
The Weibull function was the best-fit model to describe the in vitro release performance of furosemide 
reference tablets in these two dissolution apparatuses. Weibull parameters and Td values are shown in 
Table 6. No significant differences were observed in the Td data between the apparatuses (p > 0.05). 
Table 6. Weibull parameters and Td values. Mean, n = 12. 
USP Apparatus α β Ti Fmax Td ± SEM (min) 
2 (pH 5.8) 626.71 1.13 -1.99 110.39 20.89 ± 3.93 
4 (pH 6.8) 12.22 0.89 3.12 92.57 16.63 ± 1.43 
*p < 0.05 
The dissolution of furosemide reference tablets using USP Apparatus 4 exceeded the Q pharmacopoeial 
criterion (only at pH 6.8) set for certain conditions in the USP Apparatus 2. When the dissolution data of 
USP Apparatus 4 were compared with those of USP Apparatus 2 (50 rpm and phosphate buffer pH 5.8), an 
equivalent in vitro release performance was achieved based on f2, MDT, t50%, and Td comparisons. 
Under all conditions used, furosemide dissolution profiles were well described by Weibull function. The 
shape factor of the Weibull function characterises the dissolution profile as exponential (β = 1); sigmoidal, 
with upward curvature followed by a turning point (β > 1); or parabolic, with steeper initial slope consistent 
with exponential (β < 1) [28]. In this case, furosemide tablets evaluated with USP Apparatus 1 at 75 rpm and 
pH 6.8, as well as with USP Apparatus 2 at 50 rpm and pH 5.8, generated β values > 1, meaning sigmoidal 
profiles. 
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Discussion 
Several authors have studied the effect of the hydrodynamic environment on the tablet dissolution rate. 
Wu et al. [29] studied the rate process that underlies tablet dissolution to understand the role of external 
hydrodynamics on mass transfer rate and film thickness during dissolution. Shah et al. [30] stated that the 
proper medium and appropriate rotational speed of the basket and paddle are of great importance to 
assure that the test procedure used is useful and discriminatory. Additionally, Levy et al. [31] concluded 
that the in vitro dissolution rate correlates with the in vivo absorption rate only at a low agitation rate (55 
rpm). These results support the search for better dissolution schemes, especially with drugs with poor 
solubility. Poor permeability is a problem in the design of solid oral dosage forms with good bioavailability; 
thus, it is important to understand the influence of agitation rate, USP apparatus, and dissolution media on 
the in vitro release performance of class IV drugs. 
The search for adequate dissolution conditions is not limited to poorly soluble drugs or the use of USP 
Apparatuses 1 and 2. Shabir [32] indicated that the rate of in vitro release of a hydrosoluble drug can be 
accurately controlled through the USP apparatus. Shabir worked with atenolol (class III drug) generic tablets 
using USP basket and paddle apparatuses. Although these dissolution apparatuses are currently the most 
popular methods, Gao [33] explains that both methods are operated under closed finite sink conditions and 
cannot mimic the conditions in the gastrointestinal tract. The flow-through cell method has gained recent 
acceptance into the dissolution field for its versatility in the testing of novel dosage forms where traditional 
dissolution apparatuses and methods have failed [34]. 
USP Apparatus 4 has several advantages: 1. sink conditions can be maintained for poorly soluble drugs 
throughout the dissolution run; 2. it is easy to change media (suggested media is physiological pH range) 
and modify flow rate to simulate in vivo conditions; 3. it simulates intraluminal hydrodynamics efficiently; 4. 
it can be modified for different dosage forms; and 5. it measures the in vitro release rate profile as an 
output that is similar to the shape of an in vivo profile [35]. American and European pharmacopoeias 
suggest three flow rates for testing with USP Apparatus 4 (4, 8, and 16 mL/min) [36]. In this in vitro release 
study of furosemide reference tablets, we used only the flow rate of 16 mL/min as the Sotax equipment 
model CE6 has a working flow range of 10‒50 mL/min. 
Based on these characteristics, it is possible to establish a meaningful IVIVC with USP Apparatus 4. When 
a meaningful IVIVC has been established, it can be used as a surrogate for and to minimize the number of 
bioequivalence studies during drug product development [37]. Some authors have reported a better 
estimate of the absorption rate of cilostazol [19] and diclofenac sodium [20] formulations, both drugs with 
solubility problems, with the flow-through cell method. 
Some drugs can be dissolved using dissolution media in the physiological pH range (pH 1.2, 4.5, and 6.8) 
or biorelevant media, such as FaSSIF and FeSSIF (media that simulate the absence or presence of food, 
respectively) [38], to document the release performance of oral dosage forms through the gastrointestinal 
tract. This is especially important with poorly soluble drugs, such as furosemide. Based on the 
physicochemical characteristics of this drug, dissolution at low pH is not physiologically relevant. For a 
complete dissolution scheme in a physiological pH range, the Food and Drug Administration recommends 
dissolution tests with a 0.1 N hydrochloric acid or simulated gastric fluid USP without enzymes, pH 4.5 or pH 
6.8 buffer, or simulated intestinal fluid USP without enzymes [39]. The dissolution of furosemide reference 
tablets was carried out under these conditions, with the exception of simulated fluids, and the best results 
were observed with phosphate buffers at pH 5.8 and pH 6.8. More than 80 % of the drug dissolved at 60 
min and time parameters, such as MDT, t50%, and t80% were calculated. At 50 rpm, significant differences in 
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all calculated parameters (USP Apparatus 1 vs. 2) were observed. Differences between both USP 
apparatuses were expected owing to the different hydrodynamics of each apparatus; however, it is 
necessary to understand at what agitation rate this difference is more evident. Despite the wide use of USP 
Apparatuses 1 and 2 at different agitation rates, they have still been evaluated by several authors in terms 
of the surrounding hydrodynamic environments, which do not adequately reproduce the natural 
environment of the gastrointestinal tract [13-15,32,40]. 
The fitting of dissolution data to mathematical models was carried out without any physiological 
significance to discover the best equation to explain the in vitro release performance of furosemide 
reference tablets. These models were used to facilitate the analysis and interpretation of dissolution data 
because they describe the dissolution profiles as a function of the few parameters that can be statistically 
compared [41]. Han et al. [42] documented the first-order kinetics as the best-fit model to adjust 
furosemide dissolution data from commercial tablets; however, an incomplete fit scheme was created as 
only zero-order and first-order kinetics were used to adjust their dissolution data. In our study, after testing 
several equations (including common dissolution kinetics), Weibull function was the best mathematical 
model to explain the dissolution performance of furosemide. 
The development of more discriminative methods than using pharmacopoeial conditions to evaluate the 
biopharmaceutical quality of generic formulations has been documented. Studies with class II drugs, such 
as carbamazepine [43], meloxicam [44], and naproxen sodium [45], tested with USP Apparatuses 2 and 4 
have shown that USP Apparatus 2 may not reflect the dissolution performance of generic formulations and 
references. The choice of the hydrodynamic environment for the drug release is key to identify a 
meaningful IVIVC [35]. For class II drugs, IVIVCs have been identified and, with in vitro studies, they provide 
a good estimate of the absorption rate of class II drugs. Several authors have shown this important 
association only with USP Apparatus 4 [19,20,35]. However, similar dissolution profiles for USP Apparatuses 
2 and 4 have been reported for naproxen sodium tablets [45] and ibuprofen suspensions [46]. These results 
are important where no flow-through cell method is available, and an equivalent hydrodynamic 
environment is required to test solid dosage forms. 
Conclusions 
The in vitro release performance of furosemide reference tablets was determined using USP 
Apparatuses 1 and 2 at different agitation rates and dissolution media of physiological relevance. A limited 
amount of furosemide dissolved with both at pH 1.2 and 4.5. Better results were obtained with a 
dissolution medium of pH 6.8. Although USP basket and paddle apparatuses are the most widely used, it is 
important to take advantage of USP Apparatus 4 for the evaluation of furosemide tablets under the 
hydrodynamic environment that this equipment generates. All information collected is important to reduce 
the negative clinical impact that this class IV drug presents. This furosemide reference product is the 
comparative formulation for generic drug products; thus, it is important to understand the in vitro release 
performance under all possible schemes for the design of better commercial formulations. 
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